Innovating Care for Chronic Respiratory Diseases: Targeting IL-33 and Epithelial Alarmins - CME

CME

Title: Innovating Care for Chronic Respiratory Diseases: Targeting IL-33 and Epithelial Alarmins

Description: Epithelial alarmin cytokines—particularly IL-33, IL-25, and TSLP—play a key role in driving inflammation and exacerbations in respiratory diseases such as COPD, asthma, and acute viral infections. Among these, IL-33 stands out for its dual role in type-2 immune responses and antiviral defense. Prominently expressed in lung epithelial cells, IL-33 amplifies inflammatory pathways during viral infections like influenza, RSV, and SARS-CoV-2. These mechanisms contribute to exacerbations in chronic lung diseases, including asthma and COPD. At the same time, IL-33 enhances antiviral immunity by promoting cytotoxic T-cell responses, highlighting its complexity as both a therapeutic target and biomarker. Understanding these interactions can lead to innovative therapeutic strategies and improved patient outcomes in respiratory disease management. In this session, a powerhouse panel of pulmonologists, allergists/immunologists, and critical care specialists explore cutting-edge, multidisciplinary perspectives on IL-33 and other epithelial alarmins in chronic respiratory disease. Through real-world case discussions and interactive dialogue, the panel will unpack the evolving science behind airway inflammation and highlight how targeting these upstream mediators can transform personalized care.

Target Audience: Pulmonologists, Allergists/Immunologists, Critical Care Specialists, including Nurse Practitioners and Physician Assistants

Learning Objectives

Describe how IL-33, IL-25, and TSLP contribute to respiratory disease pathophysiology and exacerbations
Identify the impact of viral infections on alarmin pathways and disease progression
Analyze the role of IL-33 in driving immune responses and inflammation
Apply evidence-based strategies to manage respiratory diseases influenced by epithelial alarmins

Keywords: chronic obstructive pulmonary disease (COPD), asthma, respiratory disease management, acute viral infections, Epithelial alarmin cytokines

Disclosures and Disclaimers: National Jewish Health (“NJH”) and its officers, Board of Directors, faculty, employees, representatives, and other agents (collectively, “NJH Parties”) shall not be responsible in any capacity for, and do not warrant any content whatsoever, in any NJH publication or other product (in any medium), or the use or reliance on any such content, and expressly disclaim any and all liability for such content. All such responsibility for content and use of product solely rests with the authors or the advertisers, as the case may be. By way of example, without limiting the foregoing, this disclaimer of liability applies to the accuracy, completeness, effectiveness, quality, appearance, ideas, or products, as the case may be, of or resulting from, any statements, references, articles, positions, claimed diagnosis, claimed possible treatments, services, or advertising, express or implied, contained in any NJH live meeting, publication, online course or other product. Furthermore, the content should not be considered medical advice and is not intended to replace consultation with a qualified medical professional. Under no circumstances, including negligence, shall any of the NJH Parties be liable for any DIRECT, INDIRECT, INCIDENTAL, SPECIAL or CONSEQUENTIAL DAMAGES, or LOST PROFITS that result from any of the foregoing, regardless of legal theory and whether or not claimant was advised of the possibility of such damages.

Accredited Providers

Commercial Support

Credit Information

Credit Type	Units / Unit Type	Board
AMA PRA Category 1 Credit	1 Credits	ACCME- Accreditation Council for Continuing Medical Education